Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Product sales, net	$ 8,805,906	$ 10,304,711
Cost of products sold	3,905,092	3,992,811
Gross profit	4,900,814	6,311,900
Selling, general and administrative expenses	12,514,323	12,738,362
Research and development expenses	1,150,209	878,210
Depreciation and amortization expense	63,755	73,836
Total operating expenses	13,728,287	13,690,408
Loss from operations	(8,827,473)	(7,378,508)
Interest income (expense)	54,607	(16,360)
Gain on debt extinguishment-PPP	0	276,180
Loss before provision for income taxes and equity investments	(8,772,866)	(7,118,688)
Provision for income taxes	0	(333)
Loss before equity investment	(8,772,866)	(7,119,021)
Deferred profit and divesture-equity investment (See Note F)	0	242,589
Net loss	(8,772,866)	(6,876,432)
Net loss attributable to noncontrolling interests	66,735	58,115
Net loss attributable to Milestone Scientific Inc.	$ (8,706,131)	$ (6,818,317)
Net loss per share applicable to common stockholders—
Basic and Diluted (in dollars per share)	$ (0.12)	$ (0.10)
Weighted average shares outstanding and to be issued—
Basic and Diluted (in shares)	70,607,338	68,829,860